| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate |
2002-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19ce8132776e224557aeb6d32a5106cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf136d9dd2c03e0619f644f52e804edb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd1ea46ee2a47d0372b67a8ea7b4f575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b229e82af263a0931dc06d6e0d607271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7256b7b1447d070af33a0e9bcfad865
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aeb461c057a92aaba19ac2a6db5882e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f362c130efbc235d4179ba2d0a7587f8 |
| publicationDate |
2003-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03000175-A2 |
| titleOfInvention |
Pediatric formulation of gatifloxacin |
| abstract |
There is provided in accordance with the present invention the quinolone antibacterial gatifloxacin adequately taste-masked so that it can be utilized for pediatric formulations. A crystalline co-precipitate of gatifloxacin and one or both of stearic acid and palmitic acid in a narrow weight ratio has been found to effectively mask the bitter taste of gatifloxacin. The taste of gatifloxacin is effectively masked in the mouth and in aqueous suspension through a full dosage cycle, typically fourteen days. Gatifloxacin in the subject crystalline co-precipitates has been found to be readily available for absorption from the stomach. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10045940-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009147144-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2496501-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018129079-A1 |
| priorityDate |
2001-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |